Aquestive Therapeutics, Inc. (AQST) 2019 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, and welcome to the Aquestive Therapeutics third quarter conference call. (Operator Instructions) As a reminder, this call will be recorded.

    早安,歡迎參加 Aquestive Therapeutics 第三季電話會議。(接線員指示) 提醒您,本次通話將被錄音。

  • I would now like to introduce your host for today's conference, Ms. Stephanie Carrington, Westwicke Investor Relations. You may begin.

    現在我想介紹今天會議的主持人,Westwicke Investor Relations 的 Stephanie Carrington 女士。您可以開始了。

  • Stephanie Carrington - SVP

    Stephanie Carrington - SVP

  • Thank you, operator. Good morning and welcome to today's call to review Aquestive Therapeutics' results for the third quarter 2019 and business highlights. On today's call, I am joined by Keith Kendall, Chief Executive Officer; and John Maxwell, Chief Financial Officer, who are going to provide an overview of recent business developments and performance in the third quarter. Additional members of our leadership team will be available for Q&A. In total, we expect today's call to last approximately 60 minutes.

    謝謝,接線員。早安,歡迎參加今天的電話會議,我們將回顧 Aquestive Therapeutics 2019 年第三季的業績結果與業務重點。今天與會的還有執行長 Keith Kendall 以及財務長 John Maxwell,他們將概述第三季近期的業務進展與表現。我們領導團隊的其他成員也將出席 Q&A。整體而言,我們預期今天的電話會議約 60 分鐘。

  • As a reminder, our remarks today will correspond to the earnings release we issued after market close yesterday. In addition, a recording of today's call will be made available on Aquestive Therapeutics' website within the Investor Relations section shortly following the conclusion of this call.

    提醒各位,我們今天的發言將對應於我們在昨日收盤後發布的財報新聞稿。此外,今天會議的錄音將在本次通話結束後不久,於 Aquestive Therapeutics 官網的投資人關係專區提供。

  • To remind you, we will be discussing some non-GAAP financial measures this morning as part of our review of third quarter 2019 results. A description of these measures, along with a reconciliation to GAAP, can be found in the earnings release we issued yesterday, which is posted to the Investors section of Aquestive Therapeutics' website.

    提醒您,今天上午在回顧 2019 年第三季結果時,我們將討論部分非 GAAP 財務衡量指標。這些指標的說明以及與 GAAP 的調節表,可在我們昨日發布並張貼於 Aquestive Therapeutics 官網投資人專區的財報新聞稿中找到。

  • During the call, the company will be making forward-looking statements. We remind you of the company's safe harbor language, as outlined in yesterday's earnings release as well as the risks and uncertainties affecting the company as described in the Risk Factors section included in the company's annual report on Form 10-K filed with the SEC on March 14, 2019, and in our quarterly reports on Form 10-Q.

    在本次通話期間,公司將作出前瞻性陳述。我們提醒您注意公司的「安全港」聲明,如同昨日財報新聞稿所載,以及公司所面臨的風險與不確定性,詳述於公司於 2019 年 3 月 14 日向 SEC 提交的 Form 10-K 年報中的風險因素章節,以及我們的 Form 10-Q 季報中。

  • As with any pharmaceutical company with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to our business in the development, regulatory approval and the commercialization of our products and other matters related to operations. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. Actual results may differ materially from these statements.

    如同任何擁有研發中產品候選物與商業化產品的製藥公司,我們在產品開發、法規核准與產品商業化,以及其他營運相關事項方面,均面臨重大風險與不確定性。鑑於這些不確定性,您不應過度依賴這些前瞻性陳述;其僅反映作出陳述當日的情況。實際結果可能與這些陳述有重大差異。

  • All forward-looking statements attributable to Aquestive Therapeutics or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement and the cautionary statements contained in the earnings release issued yesterday. The company assumes no obligation to update its forward-looking statements after the date of this conference call whether a result of new information, further events or otherwise, except as required under applicable law.

    所有可歸因於 Aquestive Therapeutics 或任何代表我們行事之人士的前瞻性陳述,均在其整體上明確受本項警示聲明以及昨日發布之財報新聞稿中所載警示聲明的限制。除非適用法律另有要求,公司不承擔在本次電話會議日期之後更新前瞻性陳述的義務,不論係因新資訊、後續事件或其他原因。

  • With that, I'll now turn the line over to Keith.

    接下來,我把電話交給 Keith。

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • Thanks, Stephanie, and thanks to everyone on the call for joining us this morning as we discuss a number of important developments in our business during the third quarter and through October. John and I are going to walk through some details on our remarks today and will then be joined by additional members of the Aquestive leadership team during the Q&A session afterward.

    謝謝 Stephanie,也謝謝今天上午加入我們通話的各位。我們將討論第三季以及截至 10 月期間公司業務的多項重要進展。John 和我將帶各位走過今天發言的一些細節,之後在 Q&A 環節,我們也會有其他 Aquestive 領導團隊成員加入。

  • The third quarter was an important and successful quarter in the evolution of Aquestive. We have, as previously committed, completed our proof-of-concept study for epinephrine, AQST-108, for the treatment of allergic reactions, including anaphylaxis, and have requested a pre-IND meeting with the FDA. We've continued to grow SYMPAZAN more than 50% since the end of the last quarter and successfully completed the FDA-requested crossover study of Libervant in patients against the reference listed rectal gel.

    第三季是 Aquestive 發展演進中重要且成功的一季。我們如先前承諾,已完成用於治療過敏反應(包括過敏性休克)的腎上腺素 AQST-108 概念驗證研究,並已向 FDA 申請 pre-IND 會議。自上季末以來,我們持續推動 SYMPAZAN 成長超過 50%,並成功完成 FDA 要求的 Libervant 交叉試驗,於患者中與參考上市之地西泮直腸凝膠進行比較。

  • Let's discuss in more detail each of these key areas of focus for the company. First, let's talk about AQST-108. In late September, as promised, we completed the Phase I proof-of-concept clinical trial for AQST-108, our sublingual film formulation delivering systemic epinephrine. The proof-of-concept data demonstrated our ability to deliver systemic epinephrine via our PharmFilm formulation. Notably, we achieved similar ranges of mean values of Cmax and Tmax to that reported for injectables, EpiPen and AUVI-Q.

    接下來我們更詳細地討論公司各項關鍵重點領域。首先談 AQST-108。在 9 月下旬,如同承諾,我們完成了 AQST-108 的第一期概念驗證臨床試驗;AQST-108 為我們的舌下薄膜劑型,可遞送全身性腎上腺素。概念驗證數據顯示,我們能透過 PharmFilm 劑型遞送全身性腎上腺素。值得注意的是,我們達到的 Cmax 與 Tmax 平均值範圍,與注射劑(EpiPen 與 AUVI-Q)所報告者相近。

  • Last week, we submitted our request to the FDA for a pre-IND meeting. We are waiting for feedback from the agency regarding potential dates for this meeting to discuss the development pathway for AQST-108. At this juncture, we anticipate this meeting will be scheduled for the early part of 2020.

    上週,我們已向 FDA 提交 pre-IND 會議申請。我們正等待主管機關回覆可能的會議日期,以討論 AQST-108 的開發路徑。在此階段,我們預期該會議將安排在 2020 年初。

  • The central focus of our company at this time is our CNS franchise. As you all know, we launched SYMPAZAN at the very end of last year. SYMPAZAN is a product we believe will ultimately generate $65 million of peak annual net sales. SYMPAZAN has a meaningful value proposition for caregivers of patients suffering from Lennox-Gastaut syndrome or LGS. SYMPAZAN also represents a significant step forward in establishing our commercial infrastructure and raising the profile for Aquestive's technology as we continue to drive toward an ultimate approval and launch of Libervant.

    目前公司最核心的重點是我們的中樞神經系統(CNS)產品線。各位都知道,我們在去年年底推出了 SYMPAZAN。我們相信 SYMPAZAN 最終可帶來 6,500 萬美元的年度淨銷售額峰值。對於罹患 Lennox-Gastaut syndrome(LGS)的患者照護者而言,SYMPAZAN 具備有意義的價值主張。SYMPAZAN 也代表我們在建立商業化基礎設施、提升 Aquestive 技術能見度方面邁出重要一步,因為我們持續推進 Libervant 的最終核准與上市。

  • We launched SYMPAZAN, whose prescribers overlap greater than 90% with potential prescribers of Libervant, late last year with the aim of raising the profile of our PharmFilm technology. SYMPAZAN was developed and launched as a commercial precursor and eventual complementary product in support of the Libervant opportunity. SYMPAZAN gave us the opportunity to build out and pressure-test our commercialization capabilities and processes prior to the commercial launch of Libervant. All of our commercialization efforts relating to SYMPAZAN provide an opportunity for direct conversations with health care practitioners, patients, caregivers, advocacy groups and others about the value of the PharmFilm technology that will be the basis for Libervant.

    我們於去年年底推出 SYMPAZAN,其處方醫師與 Libervant 潛在處方醫師的重疊度超過 90%,目標是提升我們 PharmFilm 技術的能見度。SYMPAZAN 的開發與上市,是作為商業化的前導產品,並最終成為支持 Libervant 機會的互補產品。在 Libervant 商業上市之前,SYMPAZAN 讓我們有機會擴建並壓力測試我們的商業化能力與流程。我們所有與 SYMPAZAN 相關的商業化工作,讓我們能直接與醫療專業人員、患者、照護者、倡議團體及其他人士對話,說明 PharmFilm 技術的價值,而該技術將成為 Libervant 的基礎。

  • On a sequential quarterly basis, we continue to be focused on the growth and further market penetration of SYMPAZAN. The latest monthly SYMPAZAN shipment volumes to retailers has grown over 50% since the end of the second quarter. The prescribing base also continues to grow, over 56% since the second quarter, with over 83% of prescribers writing multiple scripts and over 70% of the patients refilling their scripts. Additional contracts with payers and PBMs were signed since the second quarter, and we continue to expect to achieve our goal of having over 70% of lives covered by the end of the year.

    以季度的連續性來看,我們仍專注於 SYMPAZAN 的成長與進一步的市場滲透。最新的每月 SYMPAZAN 對零售通路出貨量,自第二季末以來已成長超過 50%。處方醫師基礎也持續擴大,自第二季以來成長超過 56%;其中超過 83% 的處方醫師開立多張處方,且超過 70% 的患者會回補處方。自第二季以來,我們已與付款方與藥品福利管理機構(PBMs)簽署更多合約,並仍預期可達成我們的目標:在年底前讓超過 70% 的受保人群(lives)獲得給付涵蓋。

  • SYMPAZAN is a strategic -- is strategically accomplishing what was intended when we developed and launched the product last year. The work we do to continue to build the revenue stream and market penetration for SYMPAZAN will be an important foundation for the successful launch of Libervant expected in 2020.

    SYMPAZAN 在策略上——正策略性地達成我們去年開發並推出該產品時所預期的目標。我們持續為 SYMPAZAN 建立營收來源與市場滲透所做的工作,將成為預期於 2020 年成功推出 Libervant 的重要基礎。

  • The company's efforts are most sharply focused on bringing Libervant to market. Libervant represents a major contribution to patient care for the treatment of seizure clusters in patients with epilepsy, and we believe will potentially contribute up to $200 million to $300 million in peak net revenues. Over 1 million patients in the U.S. have active, uncontrolled epilepsy and a need for rescue medication. Less than 10% of these patients are successfully treating their seizures with the current standard of care, a rectal gel application of diazepam. A medicine is only as good as its ability to be used by patients where they need it, when they need it and in a form they accept.

    公司目前最聚焦的工作是將 Libervant 推向市場。Libervant 對於治療癲癇患者的群發性癲癇發作(seizure clusters)將對病患照護作出重大貢獻;我們相信其淨營收峰值可能達 2 億至 3 億美元。美國有超過 100 萬名患者患有活動性、未受控制的癲癇,並需要急救用藥。在目前的照護標準——地西泮直腸凝膠——之下,成功以其治療發作的患者不到 10%。一種藥物的價值,取決於患者能否在需要的地方、需要的時候,以他們可接受的形式使用它。

  • As we announced previously, during the third quarter, we successfully completed the single-dose crossover study for Libervant. We believe that we've met the specific requirements for approval communicated to us by the FDA, and our product continues to prove that it has attributes lacking in all of the current or pending formulations of diazepam.

    如我們先前所宣布,在第三季期間,我們已成功完成 Libervant 的單次劑量交叉試驗。我們相信已符合 FDA 向我們傳達的核准所需特定要求,且我們的產品持續證明其具備目前所有現有或待審的地西泮(diazepam)配方所欠缺的特性。

  • As shown in a recently completed crossover study trial comparing Libervant with a rectal gel in patients, the peak blood concentration of diazepam following buccal film administration was comparable to that of diazepam rectal gel. Also, the performance of the film measured by peak concentrations was more consistent across weight categories compared to the performance of the rectal gel. Importantly, the data continued to show that there were no nonresponders to Libervant. The rectal gel, however, continued to show, as it has historically, low and nonresponders of 10% or more in our latest study. This is a critical milestone for our lead asset and puts us on a clear and straightforward path to completing the filing of our NDA for Libervant.

    如近期完成的一項交叉試驗所示,該試驗在患者中比較 Libervant 與直腸凝膠,頰黏膜薄膜給藥後地西泮的血中峰值濃度與地西泮直腸凝膠相當。此外,以峰值濃度衡量,該薄膜在不同體重分類間的表現較直腸凝膠更為一致。重要的是,數據持續顯示對 Libervant 並無無反應者(nonresponders)。然而,直腸凝膠在我們最新研究中仍如過往一樣,持續顯示低反應者與無反應者比例達 10% 或以上。這是我們主力資產的一項關鍵里程碑,並使我們走上一條清晰且直接的道路,以完成 Libervant 的 NDA 申請遞交。

  • We filed the CMC portion of the rolling New Drug Application submission with the FDA in September. We expect to file the clinical data portion around the end of November, which will mark the completion of our submission. Assuming a 10-month review cycle, we are anticipating receiving a PDUFA goal date around the end of the third quarter of 2020.

    我們已於 9 月向 FDA 遞交滾動式新藥申請(NDA)中的 CMC(化學、製造與管制)部分。我們預期在 11 月底左右遞交臨床數據部分,這將標誌著我們遞交作業的完成。假設審查週期為 10 個月,我們預期在 2020 年第三季末左右收到 PDUFA 目標日期。

  • We believe that Libervant will become the preferred rescue medication by patients and providers looking for an alternative, potentially superior and clinically differentiated treatment to manage and interrupt seizure clusters. This is based on strong data that shows the product can be quickly and safely applied, results in consistent therapeutic levels and comes in a form preferred by patients.

    我們相信,對於尋求替代方案、且可能更優並具臨床差異化治療以管理並中斷癲癇發作群(seizure clusters)的患者與醫療提供者而言,Libervant 將成為首選的急救用藥。此判斷基於強勁數據,顯示該產品可快速且安全地使用、可達到一致的治療濃度,並以患者偏好的形式提供。

  • Based on patient survey data, Libervant is preferred by 80-plus percent of patients when compared to nasal sprays. Once approved by the FDA, Libervant will be the only treatment option usable by and delivering a consistent, predictable dose to virtually all patients to whom it's prescribed.

    根據患者調查數據,與鼻噴劑相比,超過 80% 的患者更偏好 Libervant。一旦獲 FDA 核准,Libervant 將是唯一一種幾乎可供所有被處方的患者使用,並能提供一致、可預測劑量的治療選項。

  • We plan on having a strong presence at the American Epilepsy Society annual meeting in Baltimore in early December. We have multiple poster presentations, and we're planning to hold an investor and analyst R&D event on December 9 that will feature a handful of key opinion leaders in the epilepsy field. Moreover, we're sponsoring a scientific exchange meeting at AES the morning of December 9 for clinicians and others to learn more about Libervant and the expanded clinical data set that we'll be showcasing at the meeting. We believe AES is one of the most important epilepsy conferences of the year. With the imminent filing of Libervant, we believe this is an important event for us to showcase our technology and product offerings.

    我們計畫於 12 月初在巴爾的摩舉行的美國癲癇學會(American Epilepsy Society, AES)年會上展現強勢存在感。我們將有多場海報發表,並計畫於 12 月 9 日舉辦投資人與分析師研發(R&D)活動,邀請數位癲癇領域的關鍵意見領袖(KOL)出席。此外,我們也將於 12 月 9 日上午在 AES 贊助一場科學交流會,讓臨床醫師及其他與會者更深入了解 Libervant,以及我們將在會議中展示的擴增臨床數據集。我們相信 AES 是一年中最重要的癲癇會議之一。隨著 Libervant 即將遞交申請,我們認為這是我們展示技術與產品組合的重要場合。

  • Finally, in line with our expectations, Exservan, our PharmFilm formulation of riluzole for ALS, continues to move toward a November 30 PDUFA date. As we've said previously, we're seeking to license the product outside the United States, and we've begun the process of identifying potential commercial partners in the U.S. as well.

    最後,符合我們的預期,Exservan(我們用於 ALS 的利魯唑 PharmFilm 劑型)持續朝 11 月 30 日的 PDUFA 日期推進。如我們先前所述,我們正尋求在美國以外地區授權該產品,同時也已開始在美國辨識潛在的商業合作夥伴。

  • Looking ahead for the remainder of 2019 and into 2020, we are focused on advancing our proprietary products. We will continue to grow SYMPAZAN shipments and revenue while establishing strategic relationships for us in the epilepsy market in advance of a Libervant launch. And we expect to complete the NDA filing for Libervant around the end of November, as I said before, and continue the regulatory process through the early part of 2020. We look forward to continuing to update you as we make progress on these key deliverables during the remainder of the year and in the early part of 2020.

    展望 2019 年剩餘期間及 2020 年,我們將專注於推進自有產品。我們將在 Libervant 預計於 2020 年上市前,持續提升 SYMPAZAN 的出貨與營收,同時在癲癇市場建立對我們具策略性的合作關係。並且如我先前所說,我們預期在 11 月底左右完成 Libervant 的 NDA 遞交,並在 2020 年初持續推進法規流程。我們期待在今年剩餘時間及 2020 年初,隨著這些關鍵交付項目取得進展,持續向各位更新。

  • I'll now turn the line over to John Maxwell, who'll provide specifics of our financial performance and outlook.

    接下來我把時間交給 John Maxwell,他將提供我們財務表現與展望的具體細節。

  • John T. Maxwell - Senior VP & CFO

    John T. Maxwell - Senior VP & CFO

  • Thank you, Keith. Good morning, everyone.

    謝謝你,Keith。各位早安。

  • I will use my time this morning to address the impact of our continued strong revenue performance on our guidance ranges and provide an update on our capital planning. By now, you have seen our financial results in our 10-Q and earnings release that were filed yesterday after market close. I want to draw out a few points that are important to an understanding of our updated 2019 financial guidance published in the release. To the extent that there are questions on the Q3 results, we can take those during Q&A.

    今天上午我將利用時間說明我們持續強勁的營收表現對指引區間的影響,並更新我們的資本規劃。截至目前,各位已在昨日收盤後提交的 10-Q 與財報新聞稿中看到我們的財務結果。我想提出幾點,這些對理解我們在新聞稿中發布的 2019 年更新財務指引相當重要。若對第三季(Q3)結果有任何問題,我們可在問答環節(Q&A)中討論。

  • First, Suboxone performance has been strong through the third quarter, and we are changing our Suboxone revenue outlook as a result. In the third quarter of 2019, we produced 72 million doses of Suboxone and the authorized generic product compared to about 75 million doses in Q3 of 2018. Based on the franchise's market performance and our order book, we are updating our full year guidance for Suboxone manufacturing volume to a range of 260 million to 270 million doses, up from a previous guidance of 240 million to 260 million doses. This translates into a $32 million to $33 million revenue outlook for manufacturing and supply revenue and is above the top end of our previous guidance range.

    首先,Suboxone 在第三季之前的表現一直很強勁,因此我們正在調整 Suboxone 的營收展望。2019 年第三季,我們生產了 7,200 萬劑 Suboxone 及其授權學名藥產品,相較於 2018 年第三季約 7,500 萬劑。基於該產品線的市場表現與我們的訂單簿,我們將全年 Suboxone 製造量指引更新為 2.60 億至 2.70 億劑,高於先前 2.40 億至 2.60 億劑的指引。這對應到製造與供應營收展望為 3,200 萬至 3,300 萬美元,並高於我們先前指引區間的上緣。

  • As we have discussed previously, Suboxone is an asset that represents Aquestive's past. Our future is the group of proprietary assets we are developing and commercializing, specifically SYMPAZAN, Libervant and AQST-108, epinephrine. We will continue to be the sole and exclusive supplier of Suboxone to Indivior worldwide, even as the dynamics of the U.S. market continue to change. Suboxone will remain a contributor of meaningful revenue and cash flow, even as overall revenue and volumes continue to decline into the future. We will continue to assess the impact of changes in the Suboxone market and plan to provide 2020 guidance in the first quarter.

    如我們先前討論過,Suboxone 是一項代表 Aquestive 過去的資產。我們的未來在於我們正在開發並商業化的一組自有資產,特別是 SYMPAZAN、Libervant 以及 AQST-108(腎上腺素)。即使美國市場動態持續變化,我們仍將繼續作為 Indivior 在全球範圍內 Suboxone 的唯一且獨家供應商。即便整體營收與銷量在未來持續下滑,Suboxone 仍將持續貢獻具意義的營收與現金流。我們將持續評估 Suboxone 市場變化的影響,並計畫在第一季提供 2020 年指引。

  • While we do not specifically guide on SYMPAZAN revenue, as Keith mentioned previously, our trends on wholesaler shipments to retail pharmacies and growth in new and repeat prescribers are very solid quarter-over-quarter. Our revenue recognized is affected by wholesaler inventory levels. The major wholesalers are moving us towards an inventory level as low as 7 to 14 days. The effect of this inventory management will continue to drive a disconnect between the revenue timing and our commercial market trends into 2020. As we mentioned before, we are very pleased with the commercial performance of SYMPAZAN, as this most importantly prepares us for the launch of Libervant expected in 2020.

    雖然我們不針對 SYMPAZAN 營收提供具體指引,但如 Keith 先前提到,我們在批發商出貨至零售藥局的趨勢,以及新處方與回流處方醫師的成長,季度對季度(QoQ)表現都非常穩健。我們認列的營收會受到批發商庫存水位影響。主要批發商正將我們的庫存水位降至低至 7 至 14 天。此庫存管理的影響將持續推動營收認列時點與我們商業市場趨勢之間的落差,並延續至 2020 年。如我們先前所述,我們對 SYMPAZAN 的商業表現非常滿意,因為這最重要的是讓我們為預計於 2020 年推出的 Libervant 做好準備。

  • As a result of exceeding our Suboxone and authorized generic product volume and revenue expectations for the quarter, we are raising our 2019 total revenue guidance range to $45 million to $47 million, which is above the previous guidance range. While we do not provide guidance on the other components of total revenue, all components of revenue continue to perform in line with our expectations.

    由於本季 Suboxone 與其授權學名藥產品的銷量與營收超出我們預期,我們將 2019 年總營收指引區間上調至 4,500 萬至 4,700 萬美元,高於先前的指引區間。雖然我們不對總營收的其他組成部分提供指引,但所有營收組成仍持續符合我們的預期表現。

  • Our adjusted gross margin continues to perform in line with the previous expectations. Our adjusted gross margin in the third quarter 2019 was 68%. We have left adjusted gross margin guidance unchanged as a result. Over the long term, we would expect gross margins to rise as the mix of revenue from our proprietary products rises as a component of total revenue. As with 2020 revenue, we plan to set full P&L guidance in early 2020.

    我們的調整後毛利率持續符合先前預期。2019 年第三季的調整後毛利率為 68%。因此我們維持調整後毛利率指引不變。長期而言,隨著自有產品營收在總營收中的占比提高,我們預期毛利率將上升。如同 2020 年營收指引,我們計畫在 2020 年初制定完整的損益表(P&L)指引。

  • As outlined in the earnings release issued yesterday, our full year non-GAAP adjusted EBITDA loss range has been improved to $49 million to $50 million from our previous guidance. The new guidance reflected continued strong revenue, higher costs from continued IP litigation, acceleration of the Libervant crossover trial and the costs related to the timing of our debt refinancing partially offset by cost management efforts.

    如同昨日發布的財報新聞稿所述,我們全年非 GAAP 調整後 EBITDA 虧損區間已較先前指引改善,從原先的區間調整為 4,900 萬至 5,000 萬美元。新的指引反映了營收持續強勁、持續的 IP 訴訟帶來的較高成本、Libervant 交叉試驗的加速,以及與我們債務再融資時點相關的成本;上述因素部分被成本管理措施所抵銷。

  • We have been very good at creating revenue opportunity to offset delays in key milestones like those from apomorphine, particularly with the opportunity to drive additional revenue from the melting ice cube of Suboxone. These additional revenues carry a lower gross margin than the milestone revenues we had originally expected. So this fact, combined with the pressure of the higher-cost items just mentioned, along with working capital timing, have kept pressure on our year-end cash position.

    我們一直很擅長創造營收機會,以抵銷關鍵里程碑(例如 apomorphine)延遲所帶來的影響,特別是透過 Suboxone 這個「逐漸融化的冰塊」所帶來的額外營收機會。這些額外營收的毛利率低於我們原先預期的里程碑營收。因此,這一點再加上剛才提到的較高成本項目壓力,以及營運資金時點因素,使我們年末現金部位持續承壓。

  • As a result, we're maintaining our cash burn guidance at approximately $60 million to $65 million after considering the guidance ranges and timing of working capital changes. As you know, we plan to monetize the apomorphine royalty stream once the product is approved. We are expecting this to be in the second quarter of 2020 based on Sunovion's most recent public statements. We are beginning to work now to prepare for monetization of this royalty stream, and we'll update as this develops. We continue to expect the monetization of this royalty stream could provide an additional capital of up to $100 million. After considering that noteholders will have the option to buy down debt with up to $40 million of proceeds from a monetizing event on apomorphine, we expect that the company will be left with a substantial new cash position and a reduced debt balance from this apomorphine monetization event. After completing the submission of Libervant later this month, we will evaluate accessing the first reopener as available under the indenture subject to majority lender approval.

    因此,在考量指引區間以及營運資金變動時點後,我們維持現金消耗(cash burn)指引約為 6,000 萬至 6,500 萬美元。如各位所知,我們計畫在產品獲批後將 apomorphine 權利金收入流進行變現。根據 Sunovion 最近的公開聲明,我們預期這將在 2020 年第二季發生。我們已開始著手準備該權利金收入流的變現工作,並將在進展時提供更新。我們仍預期該權利金收入流的變現可帶來最高達 1 億美元的額外資本。在考量票據持有人可選擇以 apomorphine 變現事件所得款項中最高 4,000 萬美元用於降低債務後,我們預期公司將因這次 apomorphine 變現事件而擁有可觀的新現金部位,並降低債務餘額。在本月稍晚完成 Libervant 的送件後,我們將評估在多數貸方核准的前提下,依據契約(indenture)可取得的第一個重新開放(reopener)機制。

  • In summary, our spend reflects investments in our future high-value proprietary assets, including establishing an expanding position in the epilepsy market. Our capital position has been improved by our senior notes issued in July. Our debt payments have been pushed out well beyond the expected Libervant launch, and our revenue continues to be strong from our proprietary and licensed products. Moreover, as discussed, we are optimistic as to the apomorphine royalty stream, which we expect to provide significant new capital as early as the first half of 2020.

    總結而言,我們的支出反映了對未來高價值自有資產的投資,包括在癲癇市場建立並擴大布局。我們的資本部位已因 7 月發行的優先票據而獲得改善。我們的債務償付時點已延後至遠超過預期的 Libervant 上市時間,而我們自有與授權產品的營收仍持續強勁。此外,如前所述,我們對 apomorphine 權利金收入流保持樂觀,並預期最早可在 2020 年上半年帶來可觀的新資本。

  • Operator, we will now open the line for questions.

    接線員,我們現在開放提問。

  • Operator

    Operator

  • (Operator Instructions) Our first question comes from Gary Nachman with BMO Capital Markets.

    (接線員指示) 我們的第一個問題來自 BMO Capital Markets 的 Gary Nachman。

  • Rafay Sardar

    Rafay Sardar

  • It's Rafay on for Gary. So starting with Libervant, can you comment on how familiar physicians and patients are with the product currently? And outside of AES, what activities do you plan on conducting over the next year to raise awareness? And then how should we think about the launch curve compared to what we've seen with SYMPAZAN thus far?

    我是 Rafay,代 Gary 提問。先從 Libervant 開始,能否談談目前醫師與病患對該產品的熟悉程度?以及除了 AES 之外,未來一年你們計畫進行哪些活動來提升認知度?另外,與目前為止我們在 SYMPAZAN 看到的情況相比,我們應該如何看待其上市後的導入曲線(launch curve)?

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • Ken, do you want to take that?

    Ken,你要回答這題嗎?

  • Ken W. Marshall - Senior VP & Chief Commercial Officer

    Ken W. Marshall - Senior VP & Chief Commercial Officer

  • Yes, I'm happy to. And if you look at the physician base that we currently call on, the 4,100 SYMPAZAN prescribers, they're extremely familiar with the platform and actually very familiar with the Libervant program. A good number have actually participated in the development plan.

    好的,我很樂意。如果你看我們目前拜訪的醫師基礎,也就是 4,100 位 SYMPAZAN 開立者,他們對這個平台非常熟悉,且其實也非常熟悉 Libervant 計畫。其中相當一部分實際上也參與了開發計畫。

  • If you look at what we'll do over the next 12 months, a big part of that is the scientific platform and publication strategy that supports Libervant. You'll see the front end of that at AES. We've got 5 posters going into AES. We've got a medical scientific exchange which usually draws about 200 physicians, where we'll have KOLs present that data again in a more intimate setting. We'll have 2 advisory boards, and then we'll have your normal booths there. Now the booths will be limited to talking about SYMPAZAN since that's our commercial product, but we have a big presence and allows us to talk about the platform.

    若看接下來 12 個月我們會做什麼,其中很大一部分是支持 Libervant 的科學平台與發表策略。你會在 AES 看到其中的前端成果。我們將在 AES 展出 5 份海報。我們也會舉辦醫學科學交流會,通常會吸引約 200 位醫師參與,屆時我們會邀請 KOL 在較為小型、深入的場合再次呈現這些數據。我們會有 2 場諮詢委員會(advisory boards),此外也會有一般的攤位展示。攤位部分將僅限於討論 SYMPAZAN,因為那是我們的商業化產品,但我們會有很大的曝光,並讓我們能談論這個平台。

  • If you look at that product's uptake curve, if you'll remember with SYMPAZAN, you're competing in a very small market. It's LGS. There's about 55,000 patients. About half of them are on clobazam. They're very tightly managed. They're very tough to control, and they're very slow to change. So there's a fundamentally flatter uptake curve in a market like that. When you move into a market like rescue, you move outside of just those LGS and highly refractory patients -- in those highly refractory patients into a population that is looking for a rescue strategy that may not be as severely affected as the LGS patients. So first of all, it's a bigger pool.

    如果你看該產品的導入曲線,回想一下 SYMPAZAN,你是在一個非常小的市場中競爭。那是 LGS。大約有 55,000 名病患。其中約一半使用 clobazam。他們的治療管理非常嚴格。他們非常難以控制,且改變治療非常緩慢。因此在那樣的市場中,導入曲線本質上會更平緩。當你進入像急救(rescue)這樣的市場時,你不再只侷限於 LGS 與高度難治(highly refractory)的病患——而是擴展到一個尋求急救策略的人群,這些人可能不像 LGS 病患那樣嚴重。所以首先,這是一個更大的族群池。

  • When you look at that market, it's completely dissatisfied as well. If you look at SYMPAZAN, clobazam is available. So there's some level of satisfaction. If you look at the rescue market that we'll be moving into, it's completely dissatisfied, and you can tell that by the range of ways people try to control their seizures. There's really no standard of care. So that creates a lot more interest when you come in with a preferred route of delivery for a medicine they're accustomed with. So you would expect a faster uptake.

    再看那個市場,它也完全不滿意現況。如果看 SYMPAZAN,clobazam 是可取得的。因此存在某種程度的滿意度。但若看我們將要進入的急救市場,它對現況是完全不滿意的,從人們嘗試控制癲癇發作的各種方式範圍就能看出來。基本上沒有真正的照護標準(standard of care)。因此,當你以他們熟悉的藥物、並提供偏好的給藥途徑切入時,會引發更高的興趣。所以你會預期導入更快。

  • And maybe one other point on the SYMPAZAN uptake curve. That's a fully generic market. That slows down your -- that flattens out your curve as well.

    另外也許再補充一點關於 SYMPAZAN 的導入曲線。那是一個完全學名藥化的市場。這也會讓你的——也會讓你的曲線變得更平緩。

  • Rafay Sardar

    Rafay Sardar

  • And for the epinephrine product, when do you think that could potentially come to market? What kind of penetration would that have? And how much of a need is there for a sublingual form?

    那關於腎上腺素(epinephrine)產品,你們認為它可能何時上市?它可能會有什麼樣的滲透率?以及對舌下劑型的需求有多大?

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • Go ahead, Dan.

    Dan,你來回答。

  • Daniel Barber - Senior VP & COO

    Daniel Barber - Senior VP & COO

  • This is Dan Barber. So we are -- we -- as Keith said, we just submitted our request to meet with the FDA and walk through the early part of our clinical program. We'll have clarity on that early in 2020. We're very bullish on the process we'll need to go through from a clinical perspective. So we don't see this as a long development time line, I would say in the 3- to 5-year range is a very reasonable time period to assume.

    我是 Dan Barber。如 Keith 所說,我們剛向 FDA 提交了會議申請,希望與其會面並討論我們臨床計畫的早期部分。我們將在 2020 年初對此有更清楚的了解。我們對臨床面需要走的流程非常有信心。因此我們不認為這會是一條很長的開發時程;我會說以 3 到 5 年的區間作為合理假設是相當合適的。

  • What we like about this market is, similar to Ken's comments on our Libervant product with the epinephrine anaphylaxis market, you have the same dynamics where you have devices that people don't like to use. You have a highly unsatisfied group of patients, and we think we can provide a consolidation with a new standard of care that is a big step forward for all patients.

    我們喜歡這個市場的原因是,類似 Ken 對我們 Libervant 產品的評論,在腎上腺素過敏性休克(anaphylaxis)市場中,你也有同樣的動態:人們不喜歡使用那些裝置。你有一群高度不滿意現況的病患,而我們認為我們可以透過建立新的照護標準來提供整合方案,這將是對所有病患的一大進步。

  • So in terms of penetration, I don't think we're in a place today to give you precise penetration numbers. But we see it as a disruptive force in that marketplace.

    至於滲透率,我認為我們目前還不到能提供精確滲透數字的階段。但我們將其視為該市場中的一股顛覆力量。

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • And this is Keith again. And we intend to update everyone once we finish our meeting with the FDA and have the minutes from that meeting about what the regulatory and clinical path forward is going to be so that we can fine-tune our view on development time.

    我是Keith,再次發言。我們打算在與FDA的會議結束、並取得該次會議紀要(關於未來的法規與臨床推進路徑)後,向各位更新,讓我們能夠微調對開發時程的看法。

  • Operator

    Operator

  • Our next question comes from Liana Moussatos with Wedbush Securities.

    下一個問題來自Wedbush Securities的Liana Moussatos。

  • Vasiliana Vireen Moussatos - MD of Equity Research

    Vasiliana Vireen Moussatos - MD of Equity Research

  • Can you give us a little more color on what you're doing right with SYMPAZAN growth? And with cash, what's the runway estimate?

    你們能否更具體說明一下,SYMPAZAN成長做對了哪些事?另外,就現金而言,跑道(資金可支撐期間)的估計是多少?

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • Ken, you want to take the SYMPAZAN growth?

    Ken,你要談談SYMPAZAN的成長嗎?

  • Ken W. Marshall - Senior VP & Chief Commercial Officer

    Ken W. Marshall - Senior VP & Chief Commercial Officer

  • Yes. I mean as John stated, we're very pleased with the growth of SYMPAZAN. It's performing in line with products that have come into this market before us that have filled niche like this -- niches, like BANZEL and FYCOMPA's liquids. So we're tracking in line with those.

    是的。我的意思是,如John所說,我們對SYMPAZAN的成長非常滿意。它的表現與先前進入這個市場、填補此類利基的產品一致——例如BANZEL與FYCOMPA的液體劑型。所以我們的追蹤結果與那些產品一致。

  • You're seeing really good uptake in our target physicians. To date, we've got around 350 physicians who have written the product, virtually all of them multiple times. We probably will close the year with around 400 physicians having written it. That's a very, very solid base of clinicians. We're seeing a strong refill rate. 70% refill rate is our calculation based on our copay card. So that's slightly above the industry standard. And as I mentioned, the vast majority of the physicians who are writing are writing more than once, which is a good sign. That number is 83%.

    你們會看到在我們目標醫師族群中的採用率非常好。截至目前,大約有350位醫師開立過這個產品,幾乎全部都開立過多次。我們可能在年底時,會有大約400位醫師曾開立過。這是一個非常、非常扎實的臨床醫師基礎。我們看到很強的續配率。以我們的共付額(copay)卡計算,續配率為70%。因此略高於產業標準。如我提到的,開立處方的醫師絕大多數不只開立一次,這是個好跡象。該比例是83%。

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • In terms of capital, Liana, we think we have all the options available for us to provide the capital we need. The gating factors for us are the filing of apomorphine and the filing later this month of Libervant. Apomorphine, as you know, represents a significant nondilutive capital opportunity for us. And once that is filed by Sunovion, and their public statements continue to say that, that's going to happen here shortly. But once it is filed, we'll focus on creating a transaction for that royalty stream that we think creates, as John laid out in his prepared remarks, a significant nondilutive capital stream for us going forward.

    就資本而言,Liana,我們認為我們具備所有可用選項來提供所需資金。對我們而言的關鍵門檻因素是阿朴嗎啡(apomorphine)的申報,以及本月稍晚Libervant的申報。如你所知,阿朴嗎啡對我們而言代表一個重要的非稀釋性資金機會。而一旦Sunovion完成申報——他們的公開說法也持續表示很快就會發生——應該就在近期。但一旦完成申報,我們將專注於為該權利金(royalty)現金流建立一筆交易;正如John在事先準備的發言中所概述,我們認為這將為我們未來帶來顯著的非稀釋性資金來源。

  • Operator

    Operator

  • Our next question comes from Jason Butler with JMP Securities.

    下一個問題來自JMP Securities的Jason Butler。

  • Jason Nicholas Butler - MD and Senior Research Analyst

    Jason Nicholas Butler - MD and Senior Research Analyst

  • First one, can you just give us any color on how we should think about the riluzole launch from an organizational perspective? And then secondly, on the work you're doing with 305, can you just talk a little bit more about the reformulation work? What your target profile is and any granularity on time lines?

    第一個問題,你們能否從組織角度,提供一些我們應如何看待riluzole上市(launch)的資訊?第二個問題,關於你們在305上所做的工作,能否再多談一些重新配方(reformulation)的工作?你們的目標產品特性(target profile)是什麼,以及時程上是否能提供更細的資訊?

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • Sure. Well, I'll let Dan talk about 305 and comment on that in a second.

    當然。我先讓Dan談305,稍後再對此做評論。

  • In terms of the first part of your question, as we have been indicating to everyone, our intent is to license that product first outside the U.S. and then secondly in the U.S. We are not likely to spend very much time, other than preparing to manufacture the product for a potential partner, on launching riluzole once it's approved. Jason, is that okay?

    就你問題的第一部分而言,正如我們一直向各位所表示的,我們的意圖是先在美國以外授權該產品,接著才是在美國授權。我們不太可能在riluzole獲批後花很多時間去自行推動上市,除了為潛在合作夥伴做製造準備之外。Jason,這樣可以嗎?

  • Jason Nicholas Butler - MD and Senior Research Analyst

    Jason Nicholas Butler - MD and Senior Research Analyst

  • Yes. That's great. Yes.

    可以。很好。是的。

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • Okay. Dan, you want to talk about 305?

    好的。Dan,你要談談305嗎?

  • Daniel Barber - Senior VP & COO

    Daniel Barber - Senior VP & COO

  • Sure. And on 305, we continue to work on the formulation and the -- and dialing in on the curve that we would like to see. We obviously had our results earlier this year from our PoC, and we're using those results to continue to modify the formulation as we move forward. We'll have more to say about that, I would say, at some point in time.

    當然。關於305,我們持續進行配方工作,並——並調整我們希望看到的曲線(curve)。我們今年稍早已取得概念驗證(PoC)的結果,並利用這些結果在往前推進時持續修改配方。我想我們會在某個時間點再提供更多說明。

  • Operator

    Operator

  • Our next question comes from Thomas Flaten with Lake Street Capital.

    下一個問題來自Lake Street Capital的Thomas Flaten。

  • Thomas Flaten - Senior Research Analyst

    Thomas Flaten - Senior Research Analyst

  • Just a quick question on the additional $10 million draw. Is that on submission or acceptance of file by FDA that, that would be drawable?

    關於額外1,000萬美元的提用(draw),我有個簡短問題。那是以向FDA提交(submission)或FDA受理(acceptance)檔案為條件,才可以提用嗎?

  • John T. Maxwell - Senior VP & CFO

    John T. Maxwell - Senior VP & CFO

  • That's on submission. And then we would need a majority lender approval once it's submitted. So as we indicated, we would expect that to be filed in late November. And we will reach out after that.

    是以提交為條件。然後在提交後,我們需要取得多數貸方(lender)的核准。因此如我們所指出的,我們預期會在11月下旬完成申報。之後我們會再聯繫。

  • Thomas Flaten - Senior Research Analyst

    Thomas Flaten - Senior Research Analyst

  • Got it. And then with respect to Suboxone, I know this is looking forward a bit. But given that Indivior has terminated the Sandoz agreement, should we be thinking about volumes just as branded, which is 2/3 of what they're selling? Or should we be thinking about the branded growing to take some of that share from the Sandoz volume as we look forward?

    了解。另外,關於Suboxone,我知道這有點偏向前瞻。但鑑於Indivior已終止與Sandoz的協議,我們在看未來時,是否應將銷量視為僅剩品牌(branded),也就是他們銷售量的2/3?或者我們應該預期品牌會成長,從Sandoz的那部分量中拿回一些市占?

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • I think that -- this is Keith again, Thomas. I think that the fact that the authorized generic represents about 1/3 of the market is clear. Exactly based on their actions, how much of that goes away, in other words, is absorbed by the other generics in the market. And how much, if any, is reclaimed by the brand remains to be seen. Our view is it is not all going to go away to the other generics. But what that looks like, we continue to work with Indivior to create a forecast. Right now, we're focused on delivering what's in our order book into the early part of 2020. We'll continue to work with Indivior to understand that very new market action, and we'll provide, I think, clear and specific guidance in the first quarter when we guide on 2020.

    我想——Thomas,我是Keith,再次發言。我認為授權學名藥(authorized generic)約占市場1/3這點很清楚。至於依他們的動作,這其中有多少會消失,換句話說,被市場上其他學名藥吸收多少,以及有多少(如果有的話)會被品牌收回,仍有待觀察。我們的看法是,不會全部都流向其他學名藥。但具體會是什麼樣子,我們仍在與Indivior合作建立預測。目前我們專注於把訂單簿(order book)中的出貨交付到2020年初。我們會持續與Indivior合作,以理解這個非常新的市場動態;我認為我們會在第一季提供清楚且具體的指引,當我們對2020年給出指引時。

  • Thomas Flaten - Senior Research Analyst

    Thomas Flaten - Senior Research Analyst

  • And then one final one for me. Could you talk about if it's indeed true? There was a citizen's petition filing with respect to Neurelis' intranasal product. Is -- can you talk about that, if that's indeed what you did?

    最後一個問題。你們能否談談是否屬實?據說針對Neurelis的鼻內(intranasal)產品,有人提交了公民請願(citizen's petition)。你們能談談那件事嗎?如果那確實是你們做的話。

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • There was actually a citizen's petition filed with respect to Neurelis' VALTOCO product.

    確實有人就Neurelis的VALTOCO產品提交了一份公民請願。

  • Operator

    Operator

  • (Operator Instructions) Our next question comes from Ram Selvaraju with H.C. Wainwright.

    (接線員指示) 下一個問題來自H.C. Wainwright的Ram Selvaraju。

  • Raghuram Selvaraju - MD of Equity Research & Senior Healthcare Analyst

    Raghuram Selvaraju - MD of Equity Research & Senior Healthcare Analyst

  • So I just wanted to go back to the inventory management on Libervant versus SYMPAZAN and ask if you could just give us any additional granularity and comparison between what you expect to occur with Libervant versus what you have been seeing historically with SYMPAZAN. Is there likely to be any inventory management issues in common between those 2 products? And if not, why?

    我想回到Libervant相對於SYMPAZAN的庫存管理,並請你們提供更多細節,以及你們預期Libervant會發生的情況,與你們過去在SYMPAZAN上歷史上看到的情況之間的比較。這兩個產品是否可能有任何共同的庫存管理問題?如果沒有,原因是什麼?

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • I think that remains to be seen. I think the dynamics of the 2 markets are very different. And 10 or 11 months out from that, I'm not sure we have done all the updating on Libervant because it hasn't been filed, while the submission hasn't been completed yet. I think Libervant is a very, very different market than SYMPAZAN. SYMPAZAN is highly fractioned and genericized. There's multiple product alternatives in a number of different forms, and all of the mechanisms within the market like that are at play, including inventory management.

    我認為這仍有待觀察。我認為這兩個市場的動態非常不同。而距離那個時間點還有10或11個月,我不確定我們是否已對Libervant做完所有更新,因為它尚未申報,提交也尚未完成。我認為Libervant是一個與SYMPAZAN非常、非常不同的市場。SYMPAZAN的市場高度分散且學名藥化。有多種不同形式的替代產品,而在那樣的市場中所有機制都在運作,包括庫存管理。

  • Libervant, there is no alternative. There's certainly no generic and certainly not going to be any generics when Libervant comes to that market, and you have less than 8% of the patient population accessing the standard of care for a variety of reasons. So we -- the exact dynamics of inventory management remains to be seen, but the uptake curve, regardless of how inventory is managed, we think is going to be a lot more favorable in that open market than it was and is right now for SYMPAZAN.

    Libervant,沒有替代方案。當然不會有通用版本,而且當Libervant進入那個市場時也肯定不會有任何學名藥;由於各種原因,接受標準治療的病患族群中,實際能取得治療的不到8%。因此,我們——庫存管理的確切動態仍有待觀察,但無論庫存如何管理,我們認為在那個開放市場的採用曲線將會比SYMPAZAN過去以及目前的情況更為有利。

  • Raghuram Selvaraju - MD of Equity Research & Senior Healthcare Analyst

    Raghuram Selvaraju - MD of Equity Research & Senior Healthcare Analyst

  • Okay. Great. And then with respect to what you anticipate the user experience to be for Libervant, is there anything that has emerged in your market research and your clinical assessment with this product that would lead you to believe that there might be any kind of near-term challenges to uptake upon approval based solely on patients getting more familiar with the product, physicians becoming more familiar with the product, particularly from a usage and administration standpoint?

    好的。很好。接著,關於你們預期Libervant的使用者體驗,你們在市場研究與臨床評估中是否有任何發現,會讓你們認為在核准後的短期內,僅因病患需要更熟悉產品、醫師需要更熟悉產品(特別是在使用與給藥層面),而可能對採用造成任何挑戰?

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • I'll let Ken add color to this, but absolutely not. The -- all of our polling indicates that the form is vastly preferred over what the potential alternatives might be in the market. Every one of our studies indicates that the product performs better on all the key dimensions for patients and caregivers than the current alternative and any prospective alternative. So we're very, very pleased with the outlook for this product and very pleased with the market it's going into, an underperforming standard of care with no real alternatives and no generic prospects.

    我先請Ken補充說明,但絕對不會。——我們所有的調查都顯示,這種劑型相較於市場上可能的替代方案,明顯更受偏好。我們每一項研究都顯示,該產品在所有對病患與照護者而言的關鍵面向上,都優於目前的替代方案以及任何潛在替代方案。因此,我們對這個產品的前景非常、非常滿意,也非常滿意它將進入的市場:標準治療表現不佳、沒有真正的替代方案,也沒有學名藥的可能性。

  • Ken W. Marshall - Senior VP & Chief Commercial Officer

    Ken W. Marshall - Senior VP & Chief Commercial Officer

  • Yes. And Ram, I would add a couple of places to look, and you can look at the triptan market in order of entry and where orals ultimately shook out versus nasal and injection. You can look at the allergy markets when oral decongestants or antihistamines compete with inhalation products. The orals always shake out as the preferred route of delivery. We've spent some time validating that in our market. We've asked -- we asked 60 caregivers their preference and how they would like to administer medicines. And as Keith -- I think Keith or John, one of the 2 referenced, an 83% preference for an orally administered medicine. And when you scratch that a little bit to try to understand why, you come back with a lot of very interesting attributes that I think Libervant is uniquely -- will be uniquely positioned to take advantage of.

    是的。另外,Ram,我會補充幾個可參考的例子:你可以看看曲普坦(triptan)市場,按進入順序來看,口服劑型最終相較於鼻噴與注射的結果如何。你也可以看看過敏市場,當口服減充血劑或抗組織胺與吸入式產品競爭時的情況。口服途徑總是會成為偏好的給藥方式。我們也花了一些時間在我們的市場中驗證這點。我們詢問了60位照護者他們的偏好,以及他們希望如何給藥。正如Keith——我想是Keith或John,其中一位提到的,83%偏好口服給藥的藥物。而當你再深入追問以了解原因時,你會得到許多非常有意思的屬性,我認為Libervant將——將會具備獨特的定位來加以運用。

  • The first is portability. A medicine is absolutely useless if it's not where you need it when you need it. And if you look at the various products that are in the market or coming to market, I think you would characterize all of them as not very portable. It's immediacy, it's how quickly you can get it from the package to the patients. And I think -- and you've seen our strip. You saw one when we demoed it with you. I mean it's a simple fold, tear and stick, and you've got drug going into the patient. You're not going to do that with drug-device products. I think it's painfully obvious when you look at the rectal and the nasals don't seem to simplify that or improve that very much. So there are attributes like that, that are going to separate out an orally delivered molecule from a rectally or nasally delivered molecule, and I think that'll drive our utilization.

    第一是可攜性。如果藥物在你需要的時候不在你需要的地方,那它就完全沒有用。如果你看看市場上現有或即將上市的各種產品,我想你會把它們都形容為不太便於攜帶。第二是即時性,也就是你能多快把它從包裝取出並給到病患。而我想——你也看過我們的薄膜條。我們示範給你看的時候你也看過一片。它就是簡單地折、撕、貼,就能把藥送進病患體內。藥械組合產品做不到這樣。而且很明顯,當你看直腸給藥與鼻腔給藥時,它們似乎也沒有讓流程更簡化或改善多少。所以,像這些屬性會把口服遞送的分子與直腸或鼻腔遞送的分子區隔開來,我認為這將推動我們的使用率。

  • Raghuram Selvaraju - MD of Equity Research & Senior Healthcare Analyst

    Raghuram Selvaraju - MD of Equity Research & Senior Healthcare Analyst

  • Great. Fantastic. And just on 305, can you comment on whether you expect the potential approval of Mycapssa next year to provide advantages or disadvantages for this program? Firstly, it probably would establish a clear reference framework for regulatory authorization of products in that class. But obviously, it is potentially a competitor as well. So if you could just give us some clarity on that.

    很好。太棒了。另外就305而言,你能否評論一下,你們是否預期Mycapssa明年可能獲批,會為這個計畫帶來優勢或劣勢?首先,它可能會為該類別產品的監管核准建立一個清楚的參考框架。但顯然,它也可能是一個競爭者。所以如果你能就此提供一些釐清。

  • Daniel Barber - Senior VP & COO

    Daniel Barber - Senior VP & COO

  • Yes. Ram, this is Dan. Yes, from our perspective, it would be helpful that it would be the first oral product in this space, and we think there's plenty of need and plenty of room for continued improvement over the years. I don't think that takes away, though, from our focus right now in Libervant and getting Libervant to the market and making sure that we do all the things we need to do to be successful on that front.

    是的。Ram,我是Dan。是的,從我們的角度來看,若它成為此領域第一個口服產品會有所幫助;我們認為需求很大,也有很大的空間在未來多年持續改進。不過,我不認為這會削弱我們目前對Libervant的專注:把Libervant推向市場,並確保我們完成所有需要做的事情,以在這方面取得成功。

  • Raghuram Selvaraju - MD of Equity Research & Senior Healthcare Analyst

    Raghuram Selvaraju - MD of Equity Research & Senior Healthcare Analyst

  • Okay. And then last question on the Sunovion product. Obviously, we've seen a lot of recent activity by Dainippon Sumitomo, particularly focused on the U.S. market, that has nothing to do with this product. And just wanted to know if you're seeing on the corporate levels from their side any evidence whatsoever that they are not as committed to this product as they were in the past.

    好的。最後一個問題關於Sunovion的產品。顯然,我們看到大日本住友近期有很多動作,特別聚焦在美國市場,但那與這個產品無關。我只是想了解,你們是否在他們公司層面看到任何跡象,顯示他們對這個產品的投入程度不如以往。

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • Absolutely not.

    絕對沒有。

  • Operator

    Operator

  • And I'm currently showing no further questions at this time. I'd like to turn the call back over to Keith Kendall for closing remarks.

    我目前顯示此時沒有其他問題。我想把電話交回給Keith Kendall作結語。

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • Well, as usual, thank you, everyone, for taking the time out of your busy day for -- to spend with us. We hope this update was useful to you, and we look forward to keeping you updated on all of the events we discussed today as we move into 2020. Have a great day, and we'll talk to you all soon.

    嗯,一如往常,感謝各位在忙碌的一天中撥冗——花時間與我們交流。我們希望這次更新對各位有所幫助;隨著我們邁入2020年,我們也期待就今天討論的所有事項持續向各位提供最新進展。祝各位有美好的一天,我們很快再與各位通話。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.

    各位女士、先生,今天的電話會議到此結束。感謝各位參與。您現在可以掛線。